Cargando…

FGFR Fusions in Cancer: From Diagnostic Approaches to Therapeutic Intervention

Fibroblast growth factor receptors (FGFRs) are tyrosine kinase receptors involved in many biological processes. Deregulated FGFR signaling plays an important role in tumor development and progression in different cancer types. FGFR genomic alterations, including FGFR gene fusions that originate by c...

Descripción completa

Detalles Bibliográficos
Autores principales: De Luca, Antonella, Esposito Abate, Riziero, Rachiglio, Anna Maria, Maiello, Monica Rosaria, Esposito, Claudia, Schettino, Clorinda, Izzo, Francesco, Nasti, Guglielmo, Normanno, Nicola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7555921/
https://www.ncbi.nlm.nih.gov/pubmed/32962091
http://dx.doi.org/10.3390/ijms21186856
_version_ 1783594119693598720
author De Luca, Antonella
Esposito Abate, Riziero
Rachiglio, Anna Maria
Maiello, Monica Rosaria
Esposito, Claudia
Schettino, Clorinda
Izzo, Francesco
Nasti, Guglielmo
Normanno, Nicola
author_facet De Luca, Antonella
Esposito Abate, Riziero
Rachiglio, Anna Maria
Maiello, Monica Rosaria
Esposito, Claudia
Schettino, Clorinda
Izzo, Francesco
Nasti, Guglielmo
Normanno, Nicola
author_sort De Luca, Antonella
collection PubMed
description Fibroblast growth factor receptors (FGFRs) are tyrosine kinase receptors involved in many biological processes. Deregulated FGFR signaling plays an important role in tumor development and progression in different cancer types. FGFR genomic alterations, including FGFR gene fusions that originate by chromosomal rearrangements, represent a promising therapeutic target. Next-generation-sequencing (NGS) approaches have significantly improved the discovery of FGFR gene fusions and their detection in clinical samples. A variety of FGFR inhibitors have been developed, and several studies are trying to evaluate the efficacy of these agents in molecularly selected patients carrying FGFR genomic alterations. In this review, we describe the most frequent FGFR aberrations in human cancer. We also discuss the different approaches employed for the detection of FGFR fusions and the potential role of these genomic alterations as prognostic/predictive biomarkers.
format Online
Article
Text
id pubmed-7555921
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75559212020-10-19 FGFR Fusions in Cancer: From Diagnostic Approaches to Therapeutic Intervention De Luca, Antonella Esposito Abate, Riziero Rachiglio, Anna Maria Maiello, Monica Rosaria Esposito, Claudia Schettino, Clorinda Izzo, Francesco Nasti, Guglielmo Normanno, Nicola Int J Mol Sci Review Fibroblast growth factor receptors (FGFRs) are tyrosine kinase receptors involved in many biological processes. Deregulated FGFR signaling plays an important role in tumor development and progression in different cancer types. FGFR genomic alterations, including FGFR gene fusions that originate by chromosomal rearrangements, represent a promising therapeutic target. Next-generation-sequencing (NGS) approaches have significantly improved the discovery of FGFR gene fusions and their detection in clinical samples. A variety of FGFR inhibitors have been developed, and several studies are trying to evaluate the efficacy of these agents in molecularly selected patients carrying FGFR genomic alterations. In this review, we describe the most frequent FGFR aberrations in human cancer. We also discuss the different approaches employed for the detection of FGFR fusions and the potential role of these genomic alterations as prognostic/predictive biomarkers. MDPI 2020-09-18 /pmc/articles/PMC7555921/ /pubmed/32962091 http://dx.doi.org/10.3390/ijms21186856 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
De Luca, Antonella
Esposito Abate, Riziero
Rachiglio, Anna Maria
Maiello, Monica Rosaria
Esposito, Claudia
Schettino, Clorinda
Izzo, Francesco
Nasti, Guglielmo
Normanno, Nicola
FGFR Fusions in Cancer: From Diagnostic Approaches to Therapeutic Intervention
title FGFR Fusions in Cancer: From Diagnostic Approaches to Therapeutic Intervention
title_full FGFR Fusions in Cancer: From Diagnostic Approaches to Therapeutic Intervention
title_fullStr FGFR Fusions in Cancer: From Diagnostic Approaches to Therapeutic Intervention
title_full_unstemmed FGFR Fusions in Cancer: From Diagnostic Approaches to Therapeutic Intervention
title_short FGFR Fusions in Cancer: From Diagnostic Approaches to Therapeutic Intervention
title_sort fgfr fusions in cancer: from diagnostic approaches to therapeutic intervention
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7555921/
https://www.ncbi.nlm.nih.gov/pubmed/32962091
http://dx.doi.org/10.3390/ijms21186856
work_keys_str_mv AT delucaantonella fgfrfusionsincancerfromdiagnosticapproachestotherapeuticintervention
AT espositoabateriziero fgfrfusionsincancerfromdiagnosticapproachestotherapeuticintervention
AT rachiglioannamaria fgfrfusionsincancerfromdiagnosticapproachestotherapeuticintervention
AT maiellomonicarosaria fgfrfusionsincancerfromdiagnosticapproachestotherapeuticintervention
AT espositoclaudia fgfrfusionsincancerfromdiagnosticapproachestotherapeuticintervention
AT schettinoclorinda fgfrfusionsincancerfromdiagnosticapproachestotherapeuticintervention
AT izzofrancesco fgfrfusionsincancerfromdiagnosticapproachestotherapeuticintervention
AT nastiguglielmo fgfrfusionsincancerfromdiagnosticapproachestotherapeuticintervention
AT normannonicola fgfrfusionsincancerfromdiagnosticapproachestotherapeuticintervention